Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Royalty, FKD Therapies  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Adstiladrin (nadofaragene firadenovec-vncg) / Ferring
ABLE-42, NCT06390111: A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose.

Not yet recruiting
4
25
NA
nadofaragene firadenovec, Adstiladrin
Ferring Pharmaceuticals
Bladder Cancer, Ta/T1, CIS
07/26
07/26

Download Options